Longitude Capital Partners Iii, Llc - Net Worth and Insider Trading
Longitude Capital Partners Iii, Llc Net Worth
The estimated net worth of Longitude Capital Partners Iii, Llc is at least $360 Million dollars as of 2024-12-12. Longitude Capital Partners Iii, Llc is the 10% Owner of Axonics Inc and owns about 2,933,333 shares of Axonics Inc (AXNX) stock worth over $208 Million. Longitude Capital Partners Iii, Llc is the 10% Owner of Sierra Oncology Inc and owns about 2,139,771 shares of Sierra Oncology Inc (SRRA) stock worth over $118 Million. Longitude Capital Partners Iii, Llc is also the 10% Owner of 89bio Inc and owns about 2,600,877 shares of 89bio Inc (ETNB) stock worth over $21 Million. Besides these, Longitude Capital Partners Iii, Llc also holds Inozyme Pharma Inc (INZY) , Talaris Therapeutics Inc (TALS) , Molecular Templates Inc (MTEM) . Details can be seen in Longitude Capital Partners Iii, Llc's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Longitude Capital Partners Iii, Llc has not made any transactions after 2022-04-19 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Longitude Capital Partners Iii, Llc
Longitude Capital Partners Iii, Llc Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Longitude Capital Partners Iii, Llc owns 6 companies in total, including Molecular Templates Inc (MTEM) , Inozyme Pharma Inc (INZY) , and 89bio Inc (ETNB) among others .
Insider Ownership Summary of Longitude Capital Partners Iii, Llc
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| MTEM | Molecular Templates Inc | 2020-08-28 | 10 percent owner |
| INZY | Inozyme Pharma Inc | 2022-04-19 | 10 percent owner |
| ETNB | 89bio Inc | 2020-07-10 | 10 percent owner |
 | | 2022-02-02 | 10 percent owner |
| | 2018-11-02 | 10 percent owner |
| | 2021-05-11 | 10 percent owner |
Longitude Capital Partners Iii, Llc Latest Holdings Summary
Longitude Capital Partners Iii, Llc currently owns a total of 6 stocks. Among these stocks, Longitude Capital Partners Iii, Llc owns 2,933,333 shares of Axonics Inc (AXNX) as of November 2, 2018, with a value of $208 Million and a weighting of 57.82%. Longitude Capital Partners Iii, Llc owns 2,139,771 shares of Sierra Oncology Inc (SRRA) as of February 2, 2022, with a value of $118 Million and a weighting of 32.68%. Longitude Capital Partners Iii, Llc also owns 2,600,877 shares of 89bio Inc (ETNB) as of July 10, 2020, with a value of $21 Million and a weighting of 5.81%. The other 3 stocks Inozyme Pharma Inc (INZY) , Talaris Therapeutics Inc (TALS) , Molecular Templates Inc (MTEM) have a combined weighting of 3.7% among all his current holdings.
Latest Holdings of Longitude Capital Partners Iii, Llc
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| AXNX | Axonics Inc | 2018-11-02 | 2,933,333 | 70.98 | 208,207,976 |
| SRRA | Sierra Oncology Inc | 2022-02-02 | 2,139,771 | 54.99 | 117,666,007 |
| ETNB | 89bio Inc | 2020-07-10 | 2,600,877 | 8.04 | 20,911,051 |
| INZY | Inozyme Pharma Inc | 2022-04-19 | 4,174,379 | 2.96 | 12,356,162 |
| TALS | Talaris Therapeutics Inc | 2021-05-11 | 322,078 | 2.72 | 876,052 |
| MTEM | Molecular Templates Inc | 2020-08-28 | 213,502 | 0.43 | 90,909 |
Holding Weightings of Longitude Capital Partners Iii, Llc
Longitude Capital Partners Iii, Llc Form 4 Trading Tracker
According to the SEC Form 4 filings, Longitude Capital Partners Iii, Llc has made a total of 0 transactions in Axonics Inc (AXNX) over the past 5 years. The most-recent trade in Axonics Inc is the acquisition of 533,333 shares on November 2, 2018, which cost Longitude Capital Partners Iii, Llc around $8 Million.
According to the SEC Form 4 filings, Longitude Capital Partners Iii, Llc has made a total of 1 transactions in Sierra Oncology Inc (SRRA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Sierra Oncology Inc is the acquisition of 175,000 shares on February 2, 2022, which cost Longitude Capital Partners Iii, Llc around $5 Million.
According to the SEC Form 4 filings, Longitude Capital Partners Iii, Llc has made a total of 1 transactions in 89bio Inc (ETNB) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in 89bio Inc is the acquisition of 109,090 shares on July 10, 2020, which cost Longitude Capital Partners Iii, Llc around $3 Million.
More details on Longitude Capital Partners Iii, Llc's insider transactions can be found in the Insider Trading History of Longitude Capital Partners Iii, Llc table.Insider Trading History of Longitude Capital Partners Iii, Llc
- 1
Longitude Capital Partners Iii, Llc Trading Performance
GuruFocus tracks the stock performance after each of Longitude Capital Partners Iii, Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Longitude Capital Partners Iii, Llc is 21.03%. GuruFocus also compares Longitude Capital Partners Iii, Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Longitude Capital Partners Iii, Llc within 3 months outperforms 6 times out of 10 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Longitude Capital Partners Iii, Llc's insider trading performs compared to the benchmark.
Performance of Longitude Capital Partners Iii, Llc
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 14.57 | | | | | |
| Relative Return to S&P 500(%) | 14.26 | | | | | |
Longitude Capital Partners Iii, Llc Ownership Network
Longitude Capital Partners Iii, Llc Owned Company Details
What does Molecular Templates Inc do?
Who are the key executives at Molecular Templates Inc?
Longitude Capital Partners Iii, Llc is the 10 percent owner of Molecular Templates Inc. Other key executives at Molecular Templates Inc include 10 percent owner Biotech Target N V , Chief Medical Officer Maurizio Voi , and CFO & Treasurer Sean Mclennan .
Molecular Templates Inc (MTEM) Insider Trades Summary
Over the past 18 months, Longitude Capital Partners Iii, Llc made no insider transaction in Molecular Templates Inc (MTEM). Other recent insider transactions involving Molecular Templates Inc (MTEM) include a net purchase of 3,225,499 shares made by Biotech Target N V ,
In summary, during the past 3 months, insiders sold 1,279,820 shares of Molecular Templates Inc (MTEM) in total and bought 0 shares, with a net sale of 1,279,820 shares. During the past 18 months, 1,279,820 shares of Molecular Templates Inc (MTEM) were sold and 533,688 shares were bought by its insiders, resulting in a net sale of 746,132 shares.
Molecular Templates Inc (MTEM)'s detailed insider trading history can be found in Insider Trading Tracker table.
Molecular Templates Inc Insider Transactions
Longitude Capital Partners Iii, Llc Mailing Address
Above is the net worth, insider trading, and ownership report for Longitude Capital Partners Iii, Llc. You might contact Longitude Capital Partners Iii, Llc via mailing address: 800 El Camino, Suite 220, Menlo Park Ca 94025.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
